Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CEO’ operating in the Health Care space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Ed Park
Co-Founder & CEO of Devoted Health
Follow Ed Park:
About Devoted Health: Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
_______
Hari Sundram
Chief Executive Officer of Radion Health
Follow Hari Sundram:
About QMedic, Radion Health: Radion Health offers turnkey stop-loss solutions to brokers, consultants, and TPAs.
Yingshuang Chai
Co-Founder & CEO of NuProbe
Yingshuang Chai is a Co-Founder, CEO, and Chairman of the Board of Directors at NuProbe.
Follow Yingshuang Chai:
About NuProbe: An early stage molecular diagnostics company.
Ken Cahill
CEO of SilverCloud Health
Ken Cahill is the CEO and co-founder of SilverCloud Health with offices in Boston, Dublin, and London. SilverCloud is the world’s leading digital mental health platform. It enables the delivery of clinically validated digital therapeutic care programs that are proven to significantly improve clinical outcomes, increase access & scale while reducing costs of care delivery. SilverCloud’s multi-award winning platform has spun out from 16 years of clinical research with leading academic institutions, including MIT Media Lab. Today, SilverCloud provides customized solutions for over 240 organizations globally to meet the mental health & chronic care needs of their end users/patients. The platform has been profoundly validated through the use of full randomized control trials as well as real-world data from over 250,000 active SilverCloud end users. Prior to founding SilverCloud Health, Ken held senior positions in several multinationals including, Dell, HP, and Gateway. Ken recently received the 2018 MedTech Boston 40 under 40 award.
Follow Ken Cahill:
About SilverCloud Health: SilverCloud Health provides immediate access to evidence-based and supported digital therapies.
Rachel E. Haurwitz
Co-founder, President & CEO of Caribou Biosciences
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Follow Rachel E. Haurwitz:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Noubar Afeyan
Founder & CEO of Flagship Pioneering
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm’s VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Noubar Afeyan:
About BIND Therapeutics, Cogen Therapeutics, Cygnal Therapeutics, Ensemble Therapeutics, Flagship Pioneering, Generate Biomedicines, Harvard Business School, Indigo, Joule Unlimited Technologies, Laronde, Massachusetts Institute of Technology, Moderna Therapeutics, Omega Therapeutics, Permeon Biologics, Ring Therapeutics, Rubius Therapeutics, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Daniel Grau
President, Chief Executive Officer, and Director of Sojournix
Grau co-founded and has served as Chief Executive Officer and Director at Sojournix since 2016. An experienced biotech entrepreneur and operating executive, Mr. Grau led the deal to acquire SJX-653 and has driven the rapid growth and financing of the company from startup to clinical-stage pharmaceutical business. Prior to Sojournix, Mr. Grau served as President at Heptares Therapeutics (acquired 2015), Chief Executive Officer at Cortria (acquired 2010), and Chief Operating Officer at CombinatoRx (IPO 2005). Mr. Grau currently serves as an advisor to HotSpot Therapeutics and previously served as a member of the Product Advisory Board at Concert Pharmaceuticals and as an advisor to Nimbus Therapeutics. Earlier in his career, Mr. Grau worked with multi-national pharma companies as a management consultant focused on corporate and business franchise strategy, M&A, and new product launches. Mr. Grau earned his M.Phil., M.A., and M.A.R. degrees from Yale University, where he was awarded a Mellon Fellowship, the Day Graduate Prize, and a Bass Fellowship, and a B.A. with High Honors from Davidson College, where he held a Dana Honor Scholarship, a Montgomery Scholarship, and was elected to Phi Beta Kappa.
Follow Daniel Grau:
About Cortria Corporation, Heptares Therapeutics, Sojournix: Sojournix is a biotechnology company developing innovative medicines for women’s health and endocrine disorders.
Jeffrey Morin
Co-Founder and CEO of Liteboxer
Jeffrey Morin is the founder and CEO of Liteboxer.
Follow Jeffrey Morin:
About Liteboxer: Liteboxer is a provider of a digital fitness platform used to provide an engaging full-body boxing workout.
Geoffrey Martin
President and Chief Executive Officer of CCL Industries
Geoffrey Martin joined CCL as President of CCL Label in April 2001. In May 2005 he assumed the role of President and COO of CCL Industries and President and Chief Executive Officer in May 2008. He is responsible for all CCL’s operating units including the Label, Avery and Container businesses. Martin is an international business leader with a proven track record in turnarounds, mergers and acquisitions. Prior to joining CCL, he was the Senior Group Vice President, Worldwide Converting Graphic and Specialty Tapes with Avery Dennison.
Follow Geoffrey Martin:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Lanny Sun
Co-Founder & CEO of Silicon Therapeutics
Follow Lanny Sun:
About Silicon Therapeutics: Silicon Therapeutics is a fully integrated drug design, research, and development company.
Jonathan Montagu
President & Chief Executive Officer of HotSpot Therapeutics
Follow Jonathan Montagu:
About Atlas Venture, HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Nessan Bermingham
Founder, CEO & currently Exec Chair of Triplet Therapeutics
Nessan Bermingham is founder and CEO of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chair of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner. Nessan is co-founder and was previously chief executive officer of Intellia Therapeutics. He led Intellia from seed investment and incubation at Atlas Venture through its IPO and the advancement of its gene editing platform toward clinical development. He has over ten years of experience in life science investing across venture, secondary, and public markets. Previously, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is also co-founder of Tal Medical.
Follow Nessan Bermingham:
About Korro Bio, Triplet Therapeutics: Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Jeff Albers
Chief Executive Officer of Blueprint Medicines
Jeff Albers is the chief executive officer of [Blueprint Medicines](https://www.crunchbase.com/organization/blueprint-medicines), a company engaged in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. He was previously the president of Algeta. Prior to Algeta, he served at Genzyme, where he spent seven years in senior commercial and corporate development positions. Before joining Genzyme, he spent five years as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo. He also has prior experience as a sales representative for Pfizer. Albers holds a bachelor’s degree in marketing from Indiana University and an MBA from Georgetown University.
Follow Jeff Albers:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Mirza Cifric
Co-Founder & Chief Executive Officer of Veritas Genetics
Follow Mirza Cifric:
About Veritas Genetics, YPO: Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Boris Lipchin
Founder and CEO of BRIO Systems
Boris Lipchin, co-founder and CEO of Brio Systems, Inc.. Boris was previously a co-founder and CTO of Airmada, Inc. before Airmada four years as a flight software engineer, launch operator and GN&C engineer for SpaceX.
Follow Boris Lipchin:
About Brio, BRIO Systems, Techstars: BRIO Systems offers a complete COVID-19 testing system to help employers keep teams safe and businesses on track.
Anna Villarreal
Founder & CEO of LifeStory Health Inc
Leading the first-ever discovery research into the clinical utility of menstrual blood, a recent Proof of Principle study resulted in findings of unique signatures specific to menstrual blood. On-going clinical studies aim to develop the diagnostic science further in order to support our preliminary pipeline. Anna’s resourceful leadership style and entrepreneurial experience has lead LifeStory Health, Inc. through remarkable discoveries and growth in a very short time when compared to most bioscience companies. She attributes this to her steadfast passion for and about Women’s Health. A strong advocate for women’s healthcare, Anna’s pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award winning scientific methodology has led to biomarker discovery based on precision medicine. Anna guest lectures for several graduate level programs at Northeastern University including data analytics, chemistry, regulatory affairs, and master’s in business administration. She teaches her own class in the Master’s of Biotechnology Program titled “Women’s Health: Driving Innovation and Cultural Change”. Her advocacy for women’s health continues on her podcast, “Setting the Pace”, in which she and her co-host highlight fellow female innovators.
Follow Anna Villarreal:
About CEOWORLD Magazine, LifeStory Health Inc, NEFC, The Doctor Weighs In: LifeStory Health is a biotech company committed to changing the women’s healthcare market through technology, innovation and vocalization.
Jason Krantz
CEO of Definitive Healthcare
Jason Krantz is Founder & CEO at Definitive Healthcare.
Follow Jason Krantz:
About Definitive Healthcare, Energy Acuity: Definitive Healthcare aims to transform data, analytics and expertise into healthcare commercial intelligence.
Steve Carlson
Advisor, Former CEO Obagi Medical of TRUINJECT
Follow Steve Carlson:
About : TRUINJECT™ is a software company focused on the innovation, development & commercialization of medical products for the injectable market.
Andrew Beck
Co-founder & CEO of PathAI
Andrew Beck earned a Bachelors of Arts in History from Brown University in 2002 and completed a Masters of Medical Science in Biostatistics and a Medical Degree from Brown Medical School in 2006. He completed his residency in Anatomic Pathology and clinical fellowship in Molecular Genetic Pathology from Stanford in 2010.He then joined the Advanced Residency Training at Stanford program and completed a PhD in Biomedical Informatics from Stanford University in 2013, working with Professor Daphne Koller. In 2011, he was appointed as an Assistant Professor in the Departmet of Pathology at Harvard Medical School and the Beth Israel Deaconess Medical Center. In 2016, he was promoted to Associate Professor. In 2016, Dr Beck co-founded PathAI, a company that develops artificial intelligence technology for pathology, where he serves as President and CEO.
Follow Andrew Beck:
About Beth Israel Deaconess Medical Center, PathAI: PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Aoife Brennan
CEO of Synlogic
Aoife Brennan joined Synlogic in September 2016 as chief medical officer and is responsible for the oversight and direction of the company’s clinical development strategy and operations. Aoife previously spent six years at Biogen, where she was in roles of increasing responsibility and most recently served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX™ and ELOCTATE™, treatments for Hemophilia B and Hemophilia A. Prior to joining Biogen, she was director of clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Follow Aoife Brennan:
About Synlogic: Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Terry Anderton
Founder and CEO of WAGZ
Terry Anderton is the founder and CEO of Wagz and a lifelong dog owner. Terry has a long history of building disruptive and forward-thinking technology companies, including Gemr, a social commerce platform; Trunity, a cloud-based textbook company he took public in 2012; and NitroSecurity, a network security developer acquired by Intel in 2011. Terry has also served as a Senior Sales Executive for Cabletron Systems and McAfee. He started his career leading world wide sales and launching the game of Paintball for the inventor of the game.
Follow Terry Anderton:
About WAGZ: Helping humans stay connected to their dogs through the world’s smartest dog collar.
John McQuillan
CEO of Triumvirate Environmental
Follow John McQuillan:
About Triumvirate Environmental: Triumvirate Environmental provides enterprise waste management and environmental services to healthcare, education and industrial markets.
Edward Benz
CEO of Dana-Farber Cancer Institute
Edward Benz, Jr. M.D. is President and Chief Executive Officer of Dana-Farber Cancer Institute, CEO of Dana-Farber/Partners Cancer Care as well as Principal Investigator and Director of Dana-Farber/Harvard Cancer Care and a member of the Governing Board of Dana-Farber/Children’s Hospital Cancer Center. An internationally recognized hematologist, Benz received his training at Brigham and Women’s Hospital, the National Institutes of Health, and Harvard Medical School. He is board certified in Internal Medicine and Hematology. Benz continues to be an active NIH funded investigator. He has authored over 300 peer reviewed articles, reviews, chapters and abstracts. He is a co-editor of Hematology: Principles and Practice and of the Oxford Textbook of Medicine for which he and his colleagues received the Royal Society of Authors Textbook Award. He is an associate editor of the New England Journal of Medicine. Benz’ accomplishments have been recognized by a number of distinctions, including membership in the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Science. He is a past president of the American Society of Hematology, the American Society of Clinical Investigation and the Association of American Cancer Institutes.
Follow Edward Benz:
About Dana-Farber Cancer Institute, Harvard Medical School: Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
Shantanu Gaur
Co-Founder & CEO of Allurion Technologies
Shantanu Gaur co-founded Allurion in 2009 during his second year at Harvard Medical School and is our Chief Scientific Officer. A Paul & Daisy Soros Fellow, Shantanu graduated summa cum laude and Phi Beta Kappa from Harvard College with an S.B. in Biology and significant coursework in polymer chemistry. Shantanu graduated from Harvard Medical School in 2013. He grew up in Pittsburgh, Pennsylvania and lives in Cambridge, Massachusetts.
Follow Shantanu Gaur:
About Allurion Technologies, Genetic Alliance: Allurion Technologies develops a medical device for weight loss that can be delivered and removed without surgery or endoscopy.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Derek Lo
Founder and CEO of Medallion
Derek Lo Founder and CEO of Medallion. He was previously co-founder and CEO at Py. He earned his bachelor’s degree in computer science and statistics from Yale University.
Follow Derek Lo:
About Hired, Medallion: Medallion provides a network management platform for the healthcare industry.
Khaled Kteily
Founder & CEO of Legacy
Khaled Kteily is the Founder & CEO of Legacy, a digital fertility clinic for men helping change the outdated view that fertility is a “women’s issue”. Legacy is a graduate of Harvard’s Innovation Labs and Y Combinator, has raised over $20M from top-tier investors like FirstMark Capital & Bain Capital Ventures, as well as celebrities like Justin Bieber and DJ Khaled. The company works with leading insurers, military partners, and clinics in additions to its Direct to Consumer offering. A former healthcare consultant at Oliver Wyman in Toronto, Khaled studied public policy at the Harvard Kennedy School, where he received a full scholarship and graduated with distinction. He previously graduated with a triple concentration from McGill University in Montreal, Canada. Khaled is a member of the Young Presidents Organization (YPO), is an Aspen Ideas Health Scholar, and a World Economic Forum Global Leadership Fellow. He was recently recognized as 40 under 40 by the Arab America Foundation. He serves on the boards of the Harvard Kennedy School’s Center for Public Leadership (Alumni Council) and the Harvard Arab Alumni Association.
Follow Khaled Kteily:
About Legacy: Legacy is a digital fertility clinic for men, founded at Harvard & backed by Y Combinator, FirstMark Capital, Bain Capital and celebrities.
Emad Rizk
President and Chief Executive Officer of R1 RCM
Emad Rizk currently serves as President and Chief Executive Officer of Accretive Health. He previously served as president of McKesson Health Solutions, a business unit of McKesson Corporation, and as Senior Partner and Global Director, Medical Management/Pharmacy for Deloitte Consulting. He led the company’s medical cost and quality management practice. Previous to that, he held a variety of roles at Monsanto Corporation, serving as Associate Medical Director, Corporate Medical and Scientific Affairs and then Worldwide Medical Director. Emad Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health. A Senior Scholar professor at Jefferson Medical College, Emad Rizk’s work has been widely published in medical journals and medical books. His book, The New Era of Healthcare: Practical Strategies for Providers and Payers, focuses on ways that providers and payers can work together to reduce costs while improving efficiency and patient care. In 2013, Modern Physician named Emad Rizk one of the “50 Most Influential Physician Executives in the United States,” the fifth time he has been recognized by this publication. In addition, Modern Healthcare has listed him among the “Top 100 Most Powerful People in Healthcare,” while Managed Healthcare Executive named him to its “Top 25 Leaders in Disease Management.” Emad Rizk has frequently lectured at Harvard, MIT, Wharton, Northwestern Kellogg School, and Columbia Business School.
Follow Emad Rizk:
About R1 RCM: R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models.
Ravi Ika
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
Prady Tewarie
CEO of AZOTH LLC
Tewarie Enterprises, PRT Holding Group, AZOTH LLC, Ohner
Follow Prady Tewarie:
About AZOTH LLC, Human Performance Science, The Tewarie Group LLC.: Nootropic Vitamins/Supplements
George Scangos
CEO of Vir Biotechnology
George A. Scangos, Ph.D., is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Follow George Scangos:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Ryan Boyko
Founder & CEO of Embark
Ryan Boyko is the CEO and co-founder of Embark Veterinary, Inc. Since graduating from Harvard in 2005 with a BA in Computer Science, he has used Big Data analyses to further scientific research and business development across a number of fields before targeting consumer canine genetics. After receiving an MS in Ecology and MA in Evolutionary Anthropology from the University of California at Davis, he worked to develop Big Data retail consulting analytics for Oliver Wyman. He is currently also completing a PhD in the Epidemiology of Microbial Diseases at the Yale School of Public Health. Since 2007, he has worked part time with his brother Adam on understanding the history and genetics of the domestic dog. This work has sent him to over three dozen countries and led to several publications. He has now chosen to pursue advancing canine health and genetic understanding full-time, building a company to put develop and promote the health and genetic understanding of man’s best friend.
Follow Ryan Boyko:
About Embark: Embark offers dog DNA testing that ends preventable diseases in dogs.
Adam Sachs
Co-Founder and CEO of Vicarious Surgical
Follow Adam Sachs:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Helen Adeosun
Founder & CEO of CareAcademy
Helen is CEO and Co-Founder at CareAcademy.com. She is passionate about caregiving and the impact that the right caregiver can have on families. Prior to this, Helen had worked with Teach for America, Boston Public Schools, and Pearson Education as well as a number of companies focused on caregiving issues. Care Academy was born out of her own experience as a nanny and she hopes that sittercycle.com is a place to continuously learn and share with current and future nannies. She holds a B.A. from the University of Notre Dame and an EdM. from the Harvard Graduate School of Education.
Follow Helen Adeosun:
About CareAcademy: Online training empowering senior care professionals to deliver the highest caliber of service and improve the lives of older adults.
Alicia Chong Rodriguez
Co-Founder and CEO of Bloomer Health Tech
Alicia Chong Rodriguez is the founder and CEO of Bloomer Tech. She holds two master’s degrees in engineering and management/integrated design and electrical engineering and computer science (EECS) from Massachusetts Institute of Technology (MIT).
Follow Alicia Chong Rodriguez:
About Bloomer Health Tech: Bloomer Tech uses everyday fabrics and machine learning for personalized detection, monitoring, and treatment of chronic diseases.
Michel Vounatsos
Chief Executive Officer of Biogen Idec
Michel Vounatsos is Executive Vice President and Chief Commercial Officer at Biogen. Michel brings extensive global biopharmaceutical experience and a track record of innovative stakeholder engagement to his leadership of the company’s commercial organization. Michel joined Biogen in 2016 after a 20 career at Merck, where he most recently served as President, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups, and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Michel previously held leadership positions across Europe and in China for Merck. Earlier in his career, Michel held management positions at Ciba-Geigy. Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.
Follow Michel Vounatsos:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Christopher McCann
CEO & Co-Founder of Current Health
I left school at the age of 16 and graduated with a Masters in Computer Science at age 21. At 20, I set up my first company, Dizeo – this was in social networking for children. This failed in 2011 but the experience taught me some of the most valuable lessons of my life. Around the same time, I was spending time in hospitals due to an unwell relative. I decided to go to medical school as a result in 2012. In 2014, I founded snap40 as a direct result of my experiences working in hospital. I was part of the care of patients who had deteriorated avoidably because the warning signs were detected late. I wanted a world where myself and my family would be treated preventatively at the earliest possible point. snap40 prevent illness by automatically detecting those at high risk. We’re a software company who uses our own wearable device, worn on the upper arm of the patient, to continuously monitor them. We then do predictive analytics to identify the patient who needs medical attention most and bring healthcare to them, far earlier. Please get in touch! E-mail: christopher@snap40.com
Follow Christopher McCann:
About Current Health: We help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.
Bicheng Han
CEO of BrainCo
Bicheng Han is the founder and CEO of Brainco. He founded the company in 2014. A year after, Han founded BrainRobotics. Han earned his PhD from Harvard University, Center of Brain Science. He is a brain science, medical device expert.
Follow Bicheng Han:
About BrainCo, BrainRobotics, Harvard University: BrainCo strives to apply brain machine interface (BMI) and neurofeedback training to optimize the potential of the human brain.
Shinta Nurfauzia
Co-Founder & CEO of Lemonilo
Shinta Nurfauzia is Co-Founder & CEO at Konsula.
Follow Shinta Nurfauzia:
About Lemonilo: Lemonilo is a curated marketplace for healthy food and cosmetics.
Tony Coles
Chairman and CEO of Yumanity Therapeutics
Anthony Coles was named Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, in October 2014. Prior to this, from October 2013, Anthony Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately-held company. Anthony Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company (“Onyx”), from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”). Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Anthony Coles has been a director of the Company since April 2014. He is a member of the Compensation Committee and the Finance Committee.
Follow Tony Coles:
About Yumanity Therapeutics: Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Ted Tieken
Founder and CEO of Keto and Co
Ted is the Founder and CEO of Keto and Co / Sated. Formerly cofounder and CTO of SittingAround.com
Follow Ted Tieken:
About Keto and Co, SittingAround: Keto and Co makes a growing line of ultra-low carb, ketogenic foods.
Rushika Fernandopulle
Co-Founder & Chief Executive Officer of Iora Health
Rushika Fernandopulle is Co-founder and CEO at Iora Health
Follow Rushika Fernandopulle:
About Health Rosetta Group, Iora Health: Iora Health is a healthcare company that helps patients manage their health and navigate the healthcare system.
Stephane Bancel
President and Founding CEO of Moderna Therapeutics
Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs – founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc. Stephane was previously CEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company’s market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Follow Stephane Bancel:
About Flagship Pioneering, Moderna Therapeutics, Qiagen: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Daniel R. Omstead
President and Chief Executive Officer of Tekla Capital Management
Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Follow Daniel R. Omstead:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
Christopher Garcia
CEO of Remedy Partners
Prior to his role as CEO, Chris was Vice Chairman and Chief Financial Officer at Remedy, responsible for the financial strategy, reporting, and direction for forward progress at the company. Before Remedy Partners, Chris spent two years as a Managing Partner at Enhanced Equity Funds, leading their investments in hospital supply chain management, non-emergency transport services, specialty pharmacy distribution and pain management services. In 1992, Chris formed National Healthcare Resources, an episode management company focused on managing care for work-related injuries on behalf of property and casualty insurers. During his tenure, the Company developed a specialty preferred provider group, built a telephonic case management strategy to manage episodes and hit $170 million in annual revenue before being sold to Concentra Managed Care in 2002. From 2003 to 2010, Chris spent seven years with private equity team at the Charterhouse Group as an operating partner, leading their investments in behavioral healthcare services, out-patient rehabilitation, Medicaid eligibility and business process outsourcing for healthcare claims. Chris is a Certified Public Accountant and holds a Bachelor of Science in Accounting from the University of Florida.
Follow Christopher Garcia:
About GoodCell, Remedy Partners: Remedy Partners collaborates with healthcare organizations to launch bundled payment programs.
Suelin Chen
CEO & Co-Founder of Cake
Suelin Chen is the CEO and co-founder of Cake (joincake.com), an online platform for advance care and end-of-life planning that is used by companies including Blue Cross Blue Shield of MA, Harvard Pilgrim, Liberty Mutual, and Massachusetts General Hospital. Suelin earned her BS and PhD from MIT, where she engineered new medical imaging technologies at a translational research lab at MGH. She served as the director of The Lab at Harvard, where she worked with student entrepreneurs and researchers at the Wyss Institute to commercialize their ideas. Suelin then worked as a transaction advisor to healthcare companies at IMS Health Capital before starting Cake.
Follow Suelin Chen:
About Cake: Cake is the world’s largest platform for helping people navigate end-of-life.
Evan Ehrenberg
Co-founder, CEO of Clara Health
Evan Ehrenberg is MIT’s youngest ever Ph.D. candidate in the brain and cognitive sciences department, he began the Ph.D. program at the age of 16 after graduating from UC Berkeley in 2010, and is now defending his thesis at the age of 22. Evan has past experience working at Palantir Technologies and other startups, and is an expert in cognitive and computational neuroscience research, with domain experience in human research management and recruitment. Previous: UC Berkeley, Redwood Center for Theoretical Neuroscience, Palantir Technologies
Follow Evan Ehrenberg:
About Clara Health: Clara Health empowers patients to find the right clinical trial for them.
Scott Xiao
Co-Founder & CEO of Luminopia
Scott Xiao is the Co-Founder & CEO at Luminopia.
Follow Scott Xiao:
About Luminopia: Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Kurt Graves
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Jonathan Bush
Founder and CEO of Zus Health
Jonathan Bush is the CEO and Founder of Zus Health. He is also the Chief Executive Officer, President, and Chairman of the Board of Directors. Mr. Bush co-founded athenahealth, Inc. in 1997 and has been a director since our inception. Prior to joining the Company, Mr. Bush served as an EMT for the City of New Orleans, was trained as a medic in the U.S. Army, and worked as a management consultant with Booz Allen & Hamilton. Mr. Bush obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an M.B.A. from Harvard Business School.
Follow Jonathan Bush:
About Firefly Health, Zus Health: Zus Health helps a new wave of healthcare builders to create technologies and services without the usual blockers.
Jonathan Solomon
CEO of BIOMx
Jonathan Solomon is the CEO of BiomX.
Follow Jonathan Solomon:
About BIOMx: BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.
Bill Gruber
President & CEO of Solace Therapeutics
Prior to this role as President and CEO of Solace Therapeutics, he co-founded Interlace Medical in August 2006 and served as their President and CEO until Interlace was acquired by Hologic in January 2011. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Prior to Interlace, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing. In this role, he was instrumental in creating Soteira, a Cortek subsidiary, focused on devices for treating vertebral compression fractures. Prior to Cortek, Bill spent 10 years at Boston Scientific Corporation. Before leaving Boston Scientific Corporation, he held the position of Director of the $172M Global Atherosclerotic Therapy business. Prior to entering the medical device sector, Bill spent five years in sales and marketing roles at Procter and Gamble.
Follow Bill Gruber:
About Solace Therapeutics: Solace Therapeutics develops and commercializes non-surgical office-based treatments for common bladder disorders.
Jon Heimer
CEO of Olink
As President and CEO of Olink Proteomics the vision and goal is to facilitate and implement Precision Medicine via discovery and development of validated protein targets to identify smaller protein signatures for e.g. stratification and prediction and advance them in to clinical decision making. Jon is an entrepreneur and has spent the last 25 years in various biotech start-up companies, developing and commercializing medical devices and biotech drugs. He studied economy at the Uppsala University and has an MBA from IHM Business school in Stockholm. Jon was part of a small team that started Swedens latest most successful biotech which grew to 800 people around the world, market leader in its segment, went public and eventually sold to Galderma. Prior to joining Olink Proteomics as President and CEO he ran a small orphan drug company developing two drugs into late stage clinical trials through the FDA with novel treatments for hyperoxaluria.
Follow Jon Heimer:
About Olink: Olink develops ground-breaking technologies for biomolecular analysis.
Matteo Lai
Co-founder & CEO of Empatica
Matteo Lai is co-founder and CEO of Empatica, a human data analytics company based in Milan and Boston. Empatica sells the world’s smallest and most accurate wearable sensor for research, and it recently launched Embrace, the first medical grade wearable designed to save lives for people with Epilepsy and Autism. He holds a Master in Innovation Management from Alta Scuola Politecnica. He also studied engineering, trained as an architect, and holds a Double MSc degree in Architecture from Milan’s Polytechnic and Turin’s Polytechnic.
Follow Matteo Lai:
About Empatica: Empatica is an affective computing company focused on human data analytics.
Laura D’Asaro
Co-Founder & CEO of Chirps Chips (Six Foods)
Follow Laura D’Asaro:
About Chirps Chips (Six Foods): Chirps Chips is a creating edible insect foods for healthyeating and sustainability.
Philipp Schulte
CEO of Baze
Philipp brings more than 10 years of experience in life sciences with a focus on innovation, marketing, and strategy. He is currently facing his most uphill struggle yet: getting his young daughter to have her full plate of nutrients. When he’s not at home or the office and it is cold enough he can be found trying to achieve his life goal of getting more than 100 ski days in a year.
Follow Philipp Schulte:
About Baze: Baze are enable every person to achieve their best health through a science-led, results-driven food and supplement platform.
Jean Sommadossi
Founder & Chief Executive Officer of Idenix Pharmaceuticals
Jean-Pierre Sommadossi is a veteran in the field of biotechnology. Jean Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc (NASDAQ: IDIX) and a co-Founder of Pharmasset, Inc (NASDAQ: VRUS), and served as Chairman and Chief Executive Officer of Idenix Pharmaceuticals from November 2000 to November 2010. From 1998 to November 2000, Jean Sommadossi has served as Chairman of the Board of Directors and then as Executive President and Chief Scientific Officer. Under his leadership, Idenix has raised more than $450 million in private and public equity financings and entered into multiple strategic partnerships, including those with Sumitomo and GlaxoSmithKline (GSK) as well as a landmark biotechpharma transaction with Novartis Pharma AG in 2003. Prior to founding Idenix, Jean Sommadossi was on the Faculty of The University of Alabama at Birmingham School of Medicine since March 1985. He has served as a Professor of Pharmacology, Toxicology and Clinical Pharmacology as well as an Associate Director of both the Center for AIDS Research and The Liver Center from June 1992 to November 2000. Jean Sommadossi has authored over 180 peer-reviewed publications and holds more than 50 US patents related to the treatment of Cancer and Infectious Diseases. Jean Sommadossi has earned his Pharm.D. and Ph.D. in Pharmacology degrees from the University of Marseilles in France. He was a postdoctoral Fogarty Fellow at the National Cancer Institute and the Medical College of Virginia and a recipient of a Faculty Award from The American Cancer Society. Jean Sommadossi currently is a Senior Advisor to PureTech Ventures. Jean Sommadossi was recently named to the Therapeutics Advisory Council of Harvard Medical School.
Follow Jean Sommadossi:
About Atea Pharmaceuticals, Idenix Pharmaceuticals: Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Jonathan Rennert
Chief Executive Officer of ZOLL Medical Corporation
Jonathan Rennert was named Chief Executive Officer of ZOLL in April 2016. Since joining ZOLL in 2008 as President, he has led the company to become the global leader in external defibrillation, diversified the product portfolio through the addition of transport ventilators and intrathoracic pressure regulation (IPR) therapy, and has overseen the establishment of Asahi Kasei ZOLL Medical, ZOLL’s Japanese subsidiary. Prior to joining ZOLL, Jonathan Rennert led the analytical instruments business at PerkinElmer, Inc., and earlier in his career, held manufacturing and engineering leadership positions with United Technologies and General Electric. Jonathan Rennert holds master’s degrees in management and mechanical engineering from the Massachusetts Institute of Technology (MIT) and a bachelor’s degree in mechanical and aerospace engineering from Princeton University.
Follow Jonathan Rennert:
About ZOLL Medical Corporation: ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions.
Andrew Needleman
CEO & Founder of DoseSpot
Follow Andrew Needleman:
About Claricode, DoseSpot: E-Prescribing Integration Services
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Robert Coffin
Founder and CEO of Replimune Group
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Follow Robert Coffin:
About Replimune Group: Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Roy Schoenberg
Co-Founder, Chief Executive Officer & President of Amwell
Roy Schoenberg M.D., MPH founded American Well Inc. and serves as Chief Executive Officer and President of its American Well Systems. Roy Schoenberg founded Carekey, Inc. and served as its President. He served as a Senior Vice President and Chief Internet Solutions Officer at TriZetto, following its acquisition of CareKey in December 2005. He served as Senior Associate of the Center for Clinical Computing, Beth Israel Deaconess Medical Center, Harvard Medical School. He serves as a Director of American Well Corporation. Roy Schoenberg is a frequent speaker at the American Medical Informatics Association and other conferences. He has published a number of scientific papers in leading journals. In 1998, he joined the Harvard-MIT Fellowship Program in Clinical Informatics and earned an additional MPH in Healthcare Management from the Harvard School of Public Health. Roy Schoenberg completed his Medical Training (MD) at the Hebrew University of Jerusalem.
Follow Roy Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Ido Schoenberg
Co-Founder, Chairman, and Chief Executive Officer of Amwell
do serves as the Chairman and CEO of American Well Corporation and oversees the company’s corporate strategy. Ido has a lengthy track record of successfully leading technology companies in the healthcare field. In 1996, together with Phyllis Gotlib, he co-founded iMDSoft, a provider of enterprise software that automates hospital critical care units. He grew the company into a market leader with a large multi-national install base in the U.S., Europe, and East Asia. In 2001, Ido joined CareKey Inc. as Chief Executive Officer and took the company through its acquisition by the TriZetto group. Ido served as TriZetto’s Chief Business Strategy Officer until his departure in the summer of 2006. Ido received his MD from the Sackler School of Medicine.
Follow Ido Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Ian Brady
Co-Founder & CEO of AVA
Ian Brady is the Chief Executive Officer at Hologram Sciences.
Follow Ian Brady:
About AVA, Great Marsh Brewing Company, Hologram Sciences, Plenty: AVA is a personalized, data-driven nutritional coaching solution.
Andrea Coravos
CEO and Co-founder of HumanFirst
Follow Andrea Coravos:
About HumanFirst: HumanFirst enables safe, effective, and equitable healthcare operations at home.
TJ Parker
CEO of PillPack
TJ Parker is the Co-Founder and CEO of PillPack. He is also a Board Member of RxArt. Mr. Parker is a former Pharmacist at NEPS and Founding Organizer at Hacking Medicine at MIT.
Follow TJ Parker:
About PillPack: PillPack is a full-service pharmacy that sorts medication by dose and offers door-to-door delivery.
David Coppins
Co-Founder and Chief Executive Officer of IntelyCare
David Coppins is co-founder and CEO of IntelyCare, the intelligent workforce management solution for post-acute healthcare facilities. Prior to starting IntelyCare, David served as president of Virgin Pulse, part of Sir Richard Branson’s Virgin Group. Before Virgin Pulse, David co-founded the college savings company Upromise in 1999. After Sallie Mae bought Upromise for $300M in 2006, David remained with the company and was later named CEO. Earlier in his career, David held various roles in business consulting and private equity at companies including Monitor Deloitte and Monitor Clipper Partners. David has a bachelor’s degree in business management from Brigham Young University.
Follow David Coppins:
About IntelyCare, Virgin Pulse: IntelyCare is revolutionizing healthcare staffing, scheduling, and training by offering an enterprise workforce management platform.
Craig Lund
Co Founder & CEO of Mightier
Craig Lund is a Co-Founder and Chief Executive Officer at Mightier.
Follow Craig Lund:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
Nan-Wei Gong
Co-founder & CEO of FIGUR8
Dr. Nan-Wei Gong is a researcher, engineer and serial entrepreneur. She is the co-founder and CEO of figur8 Inc, and a research affiliate of the MIT Media Lab. Her first start-up, 3dim Tech Inc, received the grand prize of the MIT $100K entrepreneurship competition in 2013, selected in the Global Founders’ Skill Accelerator and was acquired in 2014. She founded Circular2 in 2014 – a technical consulting agency that specialized in on body sensing, low-power wearable electronics and digital textile research and development. Their clients include top universities – MIT, Harvard – and fortune 500 companies such as Google and Samsung. Her past work includes flexible and customizable printed sensing surfaces for gestural control, time-of-flight modules for 3D gesture tracking, and wearable sensing for dynamic management of ubiquitous media. She publishes her research extensively at top-tier computer science conferences and journals including best papers at CHI, UbiComp, UIST and IEEE pervasive magazine. She has worked in a number of industrial research labs, among them Microsoft Research and the Nokia Research Center, and was assigned as the R&D lead of Project Jacquard at Google ATAP in 2014-2016. She holds a PhD and MS degree in Media Arts and Sciences from the MIT Media Lab and a MS in Materials Science and Engineering from National Tsing Hua University in Taiwan.
Follow Nan-Wei Gong:
About FIGUR8, MIT Media Lab: FIGUR8 is the most advanced on-body movement intelligence solution for evaluating musculoskeletal health.
Alex Adeli
Founder/CEO of Stynt
Follow Alex Adeli:
About Stynt: Simplifying healthcare staffing to enhance the quality of patient care.
Shanel Fields
Founder and CEO of MD Ally
As the child of a volunteer EMT, Shanel Fields was inspired by her father’s experiences as a first responder to launch a healthcare technology company in the 911 space that focuses on ensuring the appropriate use of finite emergency resources and improving long-term patient outcomes. In 2018, she leveraged her mobile and healthcare technology expertise to launch MD Ally, an EMS telemedicine platform that enables collaborative partnerships between public safety and provider organizations for large-scale mobile integrated healthcare initiatives. Shanel has found that driving innovation in the 911 space has fulfilled her desire to positively impact the world around her and improve the health of all citizens, particularly when they’re at their most vulnerable moments. Prior to launching MD Ally, Shanel attended Wharton Business School where she majored in Healthcare Management, Entrepreneurship and Innovation, as well as worked alongside life-long EMS researchers to study patient ER utilization and first responder advocacy. For more than a decade, she’s worked for innovative companies like AT&T and athenahealth, where she has scaled and led impact-focused growth teams focused on enterprise health systems, payers, and independent health entities.
Follow Shanel Fields:
About MD Ally: MD Ally is a telehealth company that enables a virtual response tier for 9-1-1.
David Torchiana
President & CEO of Partners HealthCare
David F. Torchiana is Member of the Board of Directors, President & CEO at Partners HealthCare.
Follow David Torchiana:
About Partners HealthCare: Partners HealthCare was founded in 1994 by Brigham and Women’s Hospital and Massachusetts General Hospital.
Jeff Valk
Chief Executive Officer of Admetsys
Follow Jeff Valk:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Robert Friel
President and Chief Executive Officer of PerkinElmer
Friel currently serves as Chairman, Chief Executive Officer and President of PerkinElmer. Prior to being appointed President and Chief Executive Officer in February 2008 and Chairman in April 2009, he had served as President and Chief Operating Officer since August 2007, and as Vice Chairman and President of our Life and Analytical Sciences unit since January 2006. Mr. Friel was our Executive Vice President and Chief Financial Officer, with responsibility for business development and information technology in addition to his oversight of our finance functions, from October 2004 until January 2006. Mr. Friel joined PerkinElmer in February 1999 as our Senior Vice President and Chief Financial Officer. Prior to joining PerkinElmer, he held several senior management positions with AlliedSignal, Inc., now Honeywell International. Mr. Friel received a Bachelor of Arts degree in economics from Lafayette College and a Master of Science degree in taxation from Fairleigh Dickinson University. Mr. Friel is currently a director of Xylem Inc. He also previously served on the national board of trustees for the March of Dimes Foundation. Mr. Friel has been one of the primary architects of PerkinElmer’s transformation into a global technology leader focused on improving the health and safety of people and the environment. Mr. Friel’s sixteen years of executive experience with PerkinElmer has allowed him to develop a broad knowledge of our operations and activities, and that operational and leadership experience has been essential in formulating appropriate business strategies. His current and past service on the boards of other public companies has provided him with additional insights about service as the Chairman of our board.
Follow Robert Friel:
About PerkinElmer: PerkinElmer is a global leader focused on improving the health and safety of people and the environment.
Daphne Zohar
Founder, CEO of PureTech Health
Daphne Zohar is the founder and managing partner of PureTech, a technology development company tackling tomorrow’s biggest healthcare challenges. Ms. Zohar was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next twenty years, and by the Boston Globe as one of the “Top 15 Innovators.” A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Akili Interactive Labs, Vedanta Bioscience, Mandara Sciences, Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.
Follow Daphne Zohar:
About PureTech Health: PureTech Health is a bio pharma company and pushes the boundaries of medicine and changing and converging healthcare ecosystem.
Waleed Hassanein
President & CEO of TransMedics
Dr. Waleed Hassanein is president , CEO and director of TransMedics, Inc. He founded the company in August, 1998. As an experienced medical device executive, Waleed brings more than eleven years of experience in establishing and leading executive teams through the clinical development, market launch and commercial rollout of the company’s breakthrough Organ Care System (OCS™) technology in the European and US markets. Waleed has successfully raised >$120 million of private equity capital to develop and commercialize the OCS™ technology and has established world-class clinical advocates for the OCS™ technology world-wide from the key opinion leaders in organ transplantation. Waleed received his M.D. from Georgetown University where he also completed two years of General Surgery residency. He completed his pre-medical education from University of London and Cairo University School of Medicine.
Follow Waleed Hassanein:
About TransMedics: Transmedics is a medical device company involved in the design and production of transplant devices.
Daniel Palestrant
Founder & CEO of Par8o
Daniel Palestrant studied at Johns Hopkins, Duke University, and Harvard Medical School. He co-founded SERMO, the largest online physician community in the world, which was acquired in 2013.
Follow Daniel Palestrant:
About Par8o: The current healthcare crisis is a uniquely American challenge and ultimately will be solved with a uniquely American solution.
Geoff MacKay
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Elisabet de los Pinos
Founder and CEO of Aura Biosciences
Follow Elisabet de los Pinos:
About Aura Biosciences: Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Robin Smith
Founder & CEO of ORIG3N
Robin Y Smith is the Founder and CEO of ORIG3N, a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases and DNA testing solutions for Health and Wellness. Visit: www.orig3n.com
Follow Robin Smith:
About ORIG3N: ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Jeffrey D. Wager
Co-Founder, Chairman & CEO of EnBiotix
Follow Jeffrey D. Wager:
About EnBiotix, Proterris: EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Paul Taheri
CEO of Yale Medical Group
Paul Taheri, MD, MBA, is Chief Executive Officer of Yale Medical Group (YMG), and a Deputy Dean at the Yale School of Medicine, providing leadership for a rapidly expanding physician organization that combines the best compassionate care with the latest in advancing medicine. He joined YMG from University of Vermont (UVM), where he was President and CEO of the UVM Medical Group in Burlington, and Senior Associate Dean for Clinical Affairs, as well as a professor of surgery. Before that he was Division Chief of Trauma, Burn and Critical Care, and then Vice Chair of Surgery at University of Michigan in Ann Arbor, where he completed his MBA at the Ross School of Business. Dr. Taheri, who is originally from Buffalo, N.Y., completed his medical degree at New York University and his general surgical residency at Tulane University. Yale Medical Group’s CEO is also the past chair of the Group on Faculty Practices for the Association of American Medical Colleges and an examiner for the American Board of Surgery. He has lectured broadly on various business topics, including cost of care, physician leadership and system optimizations.
Follow Paul Taheri:
About University of Vermont, Welsh, Carson, Anderson & Stowe, Yale Medical Group: Yale Medical Group is an academic multispecialty group that provides healthcare and medical services in the United States.
Peter Hartzbech
Founder & CEO of iMotions A/S
Peter Hartzbech passion is global entrepreneurship and building companies. Driven by a desire to make a difference in the world, he embarked upon his entrepreneurial career by starting his first venture at the age of 25. Prior to founding iMotions, he worked in Ernst & Young Denmark and Venture Cup Denmark, where he advised start-up companies on business plans, strategic and financial issues. In December 2006, Peter was appointed by Red Herring Magazine as Top 25 under 35, where the Magazine appoints Notable Entrepreneurs under 35. Peter’s positive attitude and global vision have been the main driving forces behind iMotions’ rapid growth and expansion.
Follow Peter Hartzbech:
About iMotions A/S: iMotions A/S develops and provides biometric platforms, neuromarketing, psychology, VR, and engineering solutions.
Ronald Kuerbitz
Chief Executive Officer of Upstream Rehabilitation
Ronald Kuerbitz is chief executive officer at Fresenius Medical Care North America (FMCNA). He joined FMCNA in 1996. With more than 20 years of experience in the healthcare field, Ron has held positions in business development, law, compliance, administration, and operations in both private and public organizations, including Baxter Healthcare Corporation and Caremark International Inc. From 2010-2013, Ron served as chairman of Kidney Care Partners, a coalition of patient advocates, dialysis professionals, care providers, and manufacturers dedicated to working together to improve quality of care for individuals with Chronic Kidney Disease. Kuerbitz is a graduate of Yale Law School.
Follow Ronald Kuerbitz:
About Upstream Rehabilitation: Upstream is the fifth largest and one of the fastest growing providers in the outpatient rehabilitation market.
Joe Preston
President & CEO of New Balance
Joe Preston is the President and CEO at New Balance.
Follow Joe Preston:
About New Balance: New Balance is an American multinational corporation based in the Brighton neighborhood of Boston.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Rich Gliklich
Founder and CEO of OM1
Rich Gliklich is the Founder and CEO at OM1.
Follow Rich Gliklich:
About Cyft, OM1: OM1 is a healthcare technology company that leverages real-world clinical data for medical research and personalized medicine.
Mark A. Johanson
Founder, President & CEO of Audax Medical
Mark Johanson is the Chief Executive Officer at Audax Medical.
Follow Mark A. Johanson:
About Audax Medical: Audax Medical develops instrumentation and orthopedic biomaterials for the treatment of degenerative bones and musculoskeletal tissue.
Keith M. Gottesdiener
Chief Executive Officer of Motus Therapeutics
Keith Gottesdiener is the President & CEO at Prime Medicine, Inc..
Follow Keith M. Gottesdiener:
About Motus Therapeutics, Prime Medicine: Motus Therapeutics is a biotechnology company developing peptide therapeutics for the treatment of metabolic diseases.
Jessica Nam Kim
Co-Founder & CEO of ianacare
Jessica Nam Kim is the Co-Founder and CEO at ianacare.
Follow Jessica Nam Kim:
About ianacare: ianacare is a health care company that encourages, empowers, and equips family caregivers.
Jonathan Ng
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes is applying artificial intelligence-based precision medicine to gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD).
John Maraganore
CEO of Alnylam Pharmaceuticals
Chief Executive Officer & Director at Alnylam Pharmaceuticals.
Follow John Maraganore:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals, Third Rock Ventures: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Shrenik Jain
Founder & CEO of Marigold Health
Follow Shrenik Jain:
About Marigold Health: Marigold Health uses chat support groups to make substance use treatment more engaging and personalized for vulnerable populations.
Nathan Sigworth
Co-founder and CEO of PharmaCCX
Nathan was previously co-founder and CEO of PharmaSecure where he helped accelerate adoption of serialization as the standard in global pharmaceutical supply chain. Nathan is a graduate of Dartmouth College.
Follow Nathan Sigworth:
About PharmaCCX: We are a one-stop-shop for pharmaceutical companies and payers to negotiate, price, settle, and manage complex deals more efficiently.
Jayanthi Narasimhan
Founder & CEO of WatchRx
Follow Jayanthi Narasimhan:
About WatchRx: WatchRx connects patients, caregivers, and providers to improve medication adherence
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Nikin Tharan
CEO of Medsix
Nikin believes in using technology and leveraging existing resources to challenge the status-quo and impact lives. Nikin discovered he had a talent for electronics and started working at a lab affiliated with the Border Security Force in India at 9 y/o. He successfully piloted projects on agricultural management, anti-train collision, smart homes and got a honorable citation from the President of India. In his role as the President of WISE, Nikin improved STEM education at low-income schools in India through an innovative experiential education curriculum. Over the summer of 2015, he conducted an impact assessment of the non-profit with a research grant from Northeastern which helped WISE go national. Nikin got a full scholarship to attend Northeastern at 16 y/o. After the Harvard-MIT hackathon on iCorruption, he worked at Harvard Law School with Prof. Lawrence Lessig to research ways to reduce bias in academia. At HackingEDU 2015, he co-founded ITAP, a social enterprise that creates IT apprenticeship program for disadvantaged youth in the Bay Area. ITAP got selected for the Clinton Global Initiative University 2016, again in 2017, shortlisted for their Innovation Fund and secured a grant from Northeastern. For the latter half of 2016, Nikin was a Visiting Innovation Fellow at John Hancock’s Lab of Forward Thinking. In early 2017, he helped set up the world’s first open innovation platform with IoT at Northeastern. At MIT HackingMedicine, his team won two prizes and he co-founded Medsix, a medtech startup focused on post operative recovery management. After graduating, Nikin worked on commercializing the world’s first nanomaterial-based ion detector at Guardion and is an alumnae of the Techstars-US Air Force accelerator. He raised $250k for Medsix and now works there full-time. He enjoys reading, listening to podcasts, networking and being a mentor to millennial entrepreneurs.
Follow Nikin Tharan:
About Medsix: Novel wound drainage monitoring sensors + predictive tools for better patient outcomes
Stuart Koman
Founder, President & CEO of Walden Behavioral Care
Stuart Koman, Ph.D. is a founder and the Chief Executive of Walden Behavioral Care and its non-profit sister corporation, the Walden Center for Education and Research. Dr. Koman is a veteran health care manager with more than 30 years of experience leading and developing several behavioral health care companies. While all of these companies have become successful businesses under his leadership, Dr. Koman attributes much of this success to another common theme: they have all taken seriously their mission of providing innovative, compassionate and coordinated services to previously under served populations and families. Walden Behavioral Care is the most recent example as it has quickly become the leading provider of services for individuals with eating disorders in New England through its multi-level, multi-site system of care. In the nine year period 2003-2012, Walden has become a state of the art system of care providing some 40,000 service units annually at its primary campus in Waltham (MA) and satellite centers in Braintree (MA), Worcester (MA), Northampton (MA) and South Windsor, Connecticut. Dr. Koman began his professional career in 1985 when he was appointed senior clinician and then Director of Adolescent Programs at Charles River Hospital (CRH) in Wellesley, MA. Over the next 10 years (1985 to 1996), he led two companies in achieving significant clinical and business outcomes. The first company, Charles River Management (CRHM), a subsidiary of CRH, grew out of the work of Dr. Koman and others in developing innovative treatment models for adolescents in hospital settings. Dr. Koman and his colleagues were among the first to recognize the central importance of the family in treatment program design. Many of these and related ideas were published in the Handbook of Adolescents and Family Therapy, an effort in which Dr. Koman wrote several chapters and served as co-editor. In 1990, Dr. Koman co-founded the managed health care company, Choate Health Systems, Inc. (CHSI). Similar to the approach at Charles River, Choate provided integrated delivery of behavioral health care through a full continuum of treatment services operating under one administration. As this model proved highly adaptive in the emerging world of managed care, Choate expanded rapidly, and this led to the formation of Choate Health Management, Inc. (CHMI) and Choate Psychiatric Associates, P.C. (CPA). Having successfully managed the transition in health care reimbursement approaches, Dr. Koman was asked to assist the profession of psychology to do the same and subsequently served on the Governing Board of the American Psychological Association’s practice division from 1992-2000. After leaving Choate in 1995, Dr. Koman started Koman Associates, a firm that focuses on leaders and leadership issues in government, health care and business. At the same time, Dr. Koman served as Senior Clinical Adviser for Public Consulting Group providing strategic planning and systems re-engineering to state agencies throughout the United States. Dr. Koman continues his involvement with both of these organizations albeit on a much reduced basis once Walden was established in 2003. Dr. Koman earned his Bachelor of Science degree from Trinity College and his Ph.D. from Duke University.
Follow Stuart Koman:
About Walden Behavioral Care: Walden Behavioral Care, a Waltham, Mass.-based provider of behavioral health services for individuals with eating disorders.
Chris Peng
Co-founder & CEO of Labfront
At kiipo, Chris utilizes his experience in product development from his work on several products starting with his work at HTC on the Dynamical Biomarkers Group’s entry into the Tricorder XPRIZE. Since then, he managed the design and engineering effort in the creation of Ethiopia’s first Emergency Medical System. Although his background is electrical and software engineering, he is passionate about designing for social impact. Prior to his time at HTC, he spent 6 months as a volunteer in Northern Thailand where he taught technology skills to underprivileged children as a ladder out of poverty. Chris also worked with local nonprofits to improve their business models. Thailand was his first foray into sustainable social impact, since then he’s done work in Ethiopia, China, and Taiwan.
Follow Chris Peng:
About Labfront: Labfront elevates your research findings by simplifying physiological data collection and management.
